Scarica l'app Stockscreener
134.25
1.14%
-1.55
Dopo l'orario di chiusura:
134.25
Precedente Chiudi:
$135.80
Aprire:
$136.03
Volume 24 ore:
646.27K
Relative Volume:
0.87
Capitalizzazione di mercato:
$8.14B
Reddito:
$4.09B
Utile/perdita netta:
$-404.84M
Rapporto P/E:
-19.90
EPS:
-6.7469
Flusso di cassa netto:
$1.24B
1 W Prestazione:
-2.82%
1M Prestazione:
+6.09%
6M Prestazione:
+32.20%
1 anno Prestazione:
+16.08%
Intervallo 1D:
$133.72
$137.43
Intervallo di 1 settimana:
$132.41
$139.00
Portata 52W:
$95.49
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Nome
Jazz Pharmaceuticals Plc
Settore
Industria
Telefono
353-1-634-7800
Indirizzo
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Confronta JAZZ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
134.25 | 8.12B | 4.09B | -404.84M | 1.24B | -6.7469 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-15 | Iniziato | Deutsche Bank | Buy |
| 2025-03-07 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Iniziato | Goldman | Buy |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-27 | Downgrade | UBS | Buy → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Mkt Perform |
| 2023-06-12 | Ripresa | Wells Fargo | Equal Weight |
| 2022-12-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-11-19 | Ripresa | Goldman | Buy |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-10-05 | Iniziato | Citigroup | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-05-19 | Ripresa | JP Morgan | Overweight |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-14 | Downgrade | Goldman | Neutral → Sell |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Iniziato | Jefferies | Buy |
| 2020-03-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Neutral |
| 2019-08-21 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Peer Perform |
| 2018-11-08 | Reiterato | B. Riley FBR | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Reiterato | H.C. Wainwright | Neutral |
| 2018-03-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
Praxis Has Unexpected Hits In Two Phase II Essential Tremor Studies - insights.citeline.com
Jazz Denied Preferred Drug Royalty Rate, But Still Gets Boost - Law360
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025 - GlobeNewswire Inc.
Will FDA Approval of Zepzelca Combo Redefine Jazz Pharmaceuticals' (JAZZ) Position in Lung Cancer Treatment? - simplywall.st
Will Jazz Pharmaceuticals plc (J7Z) stock announce special dividend2025 Fundamental Recap & Accurate Trade Setup Notifications - newser.com
What institutional flow reveals about Jazz Pharmaceuticals plcInsider Selling & Free Verified High Yield Trade Plans - newser.com
Why Jazz Pharmaceuticals plc stock is seen as undervaluedInsider Buying & Daily Stock Trend Watchlist - newser.com
Is Jazz Pharmaceuticals plc stock a buy before product launchesWeekly Trading Summary & Real-Time Volume Analysis - newser.com
Jazz Pharmaceuticals plc stock outlook for YEARWeekly Market Summary & Comprehensive Market Scan Insights - newser.com
Improved Revenues Required Before Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) Shares Find Their Feet - 富途牛牛
Is Jazz Pharmaceuticals plc showing signs of accumulationEarnings Growth Summary & Technical Buy Zone Confirmations - newser.com
When is the best time to exit Jazz Pharmaceuticals plc2025 Investor Takeaways & Weekly Consistent Profit Watchlists - newser.com
Callan Family Office LLC Buys New Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Is Jazz Pharmaceuticals plc stock attractive for passive investors2025 Trade Ideas & Weekly Watchlist for Hot Stocks - newser.com
Order flow analysis tools used on Jazz Pharmaceuticals plcJuly 2025 Snapshot & Consistent Income Trade Recommendations - newser.com
Jazz Pharmaceuticals plc’s volatility index tracking explained2025 EndofYear Setup & Fast Momentum Entry Tips - newser.com
Will Jazz Pharmaceuticals plc benefit from macro trendsGap Up & Free Reliable Trade Execution Plans - newser.com
Forecasting Jazz Pharmaceuticals plc price range with options dataEarnings Growth Report & Stepwise Swing Trade Plans - newser.com
How strong is Jazz Pharmaceuticals plc stock revenue growthEntry Point & Low Drawdown Trading Strategies - newser.com
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: A 38% Upside Potential with Robust Analyst Support - DirectorsTalk Interviews
Q3 EPS Forecast for Jazz Pharmaceuticals Reduced by Analyst - MarketBeat
Full technical analysis of Jazz Pharmaceuticals plc stockWeekly Volume Report & Smart Money Movement Alerts - newser.com
Published on: 2025-10-12 20:45:57 - newser.com
Assessing Jazz Pharmaceuticals (JAZZ) Valuation Following Strong Recent Share Price Momentum - Yahoo Finance
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Meritage Portfolio Management - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by KLP Kapitalforvaltning AS - MarketBeat
Jazz Pharmaceuticals (JAZZ): Assessing Valuation Following Recent Net Income Growth and Share Price Recovery - simplywall.st
Zacks Research Has Positive Forecast for JAZZ Q2 Earnings - MarketBeat
Lmcg Investments LLC Lowers Stake in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Cannabis Market Trends and Company Analysis 2025-2033 Featuring Canopy Growth, Tilray Brands, Curaleaf, Aurora, Jazz Pharma, Green Thumb Industries, Trulieve, Cresco Labs, Organigram, TerrAscend - Yahoo Finance
United States Idiopathic Hypersomnia Treatment Market: Jazz Pharmaceuticals & Emerging Competitors - openPR.com
Leerink Partnrs Has Bearish Estimate for JAZZ Q3 Earnings - MarketBeat
Jazz Pharmaceuticals (JAZZ) Receives a Buy from Truist Financial - The Globe and Mail
Jazz Pharmaceuticals (JAZZ) Gets a Buy from Bank of America Securities - The Globe and Mail
Will Jazz Pharmaceuticals plc stock keep outperforming rivalsBuy Signal & Safe Capital Growth Plans - newser.com
BofA Adjusts Price Target on Jazz Pharmaceuticals Public to $230 From $225 - MarketScreener
Weiss Ratings Reiterates "Sell (D)" Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) - MarketBeat
Is Jazz Pharmaceuticals plc a candidate for recovery playMarket Trend Review & High Conviction Buy Zone Picks - newser.com
Jazz Pharmaceuticals Plc Azioni (JAZZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Jazz Pharmaceuticals Plc Azioni (JAZZ) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| COZADD BRUCE C | Director |
Oct 01 '25 |
Sale |
131.78 |
2,000 |
263,560 |
412,326 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):